Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Breast and prostate cancer risk: the interplay of polygenic risk, high-impact monogenic variants, and family history

View ORCID ProfileEmadeldin Hassanin, View ORCID ProfilePatrick May, View ORCID ProfileRana Aldisi, Isabel Spier, View ORCID ProfileAndreas J. Forstner, View ORCID ProfileMarkus M. Nöthen, Stefan Aretz, View ORCID ProfilePeter Krawitz, Dheeraj Reddy Bobbili, View ORCID ProfileCarlo Maj
doi: https://doi.org/10.1101/2021.06.04.21258277
Emadeldin Hassanin
1Institute for Genomic Statistics and Bioinformatics, University Hospital Bonn, Bonn, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Emadeldin Hassanin
Patrick May
2Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Patrick May
Rana Aldisi
1Institute for Genomic Statistics and Bioinformatics, University Hospital Bonn, Bonn, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rana Aldisi
Isabel Spier
3Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany
4National Center for Hereditary Tumor Syndromes, University Hospital Bonn, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas J. Forstner
3Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany
5Centre for Human Genetics, University of Marburg, Marburg, Germany
6Institute of Neuroscience and Medicine (INM-1), Research Center Jülich, Jülich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andreas J. Forstner
Markus M. Nöthen
3Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Markus M. Nöthen
Stefan Aretz
3Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany
4National Center for Hereditary Tumor Syndromes, University Hospital Bonn, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Krawitz
1Institute for Genomic Statistics and Bioinformatics, University Hospital Bonn, Bonn, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Peter Krawitz
Dheeraj Reddy Bobbili
2Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlo Maj
1Institute for Genomic Statistics and Bioinformatics, University Hospital Bonn, Bonn, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Carlo Maj
  • For correspondence: cmaj@uni-bonn.de
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Purpose Investigate to which extent polygenic risk scores (PRS), high-impact monogenic variants, and family history affect breast and prostate cancer risk by assessing cancer prevalence and cancer cumulative lifetime incidence.

Methods 200,643 individuals from the UK Biobank were stratified as follows: 1. carriers or non-carriers of high impact constitutive, monogenic variants in cancer susceptibility genes, 2. high or non-high PRS (90th percentile threshold), 3. with or without a family history of cancer.

Multivariable logistic regression was used to compare the odds ratio (OR) across the different groups while Cox proportional hazards models were used to compute the cumulative incidence through life.

Results Breast and prostate cancer cumulative incidence by age 70 is 7% and 5% for non-carriers with non-high PRS and reaches 37% and 32% among carriers of high-impact variants in cancer susceptibility genes with high PRS.

The additional presence of family history is associated with a further increase of the risk of developing cancer reaching an OR of 14 and 21 for breast and prostate cancer, respectively.

Conclusion High PRS confers a cancer risk comparable to high-impact monogenic variants. Family history, monogenic variants, and PRS contribute additively to breast and prostate cancer risk.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Patrick May was supported by the Luxembourg National Research Fund (FNR) as part of the National Centre of Excellence in Research on Parkinson disease (NCER-PD/FNR11264123) and the DFG Research Units FOR2715 (INTER/DFG/17/11583046) and FOR2488 (INTER/DFG/19/14429377). Carlo Maj and Emadeldin Hassanin are supported by the BONFOR-program of the Medical Faculty University of Bonn (O-147.0002). Stefan Aretz and Isabel Spier are members of the European Reference Network on Genetic Tumor Risk Syndromes (ERN GENTURIS) -Project ID No 739547. The authors acknowledge the use of de.NBI cloud and the support by the High Performance and Cloud Computing Group at the Zentrum for Datenverarbeitung of the University of Tubingen and the Federal Ministry of Education and Research (BMBF) through grant no 031A535A.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

all ethical guidelines have been followed

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Genome-wide genotyping data, exome-sequencing data, and phenotypic data from the UK Biobank are available upon successful project application.

https://www.ukbiobank.ac.uk/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted June 09, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Breast and prostate cancer risk: the interplay of polygenic risk, high-impact monogenic variants, and family history
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Breast and prostate cancer risk: the interplay of polygenic risk, high-impact monogenic variants, and family history
Emadeldin Hassanin, Patrick May, Rana Aldisi, Isabel Spier, Andreas J. Forstner, Markus M. Nöthen, Stefan Aretz, Peter Krawitz, Dheeraj Reddy Bobbili, Carlo Maj
medRxiv 2021.06.04.21258277; doi: https://doi.org/10.1101/2021.06.04.21258277
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Breast and prostate cancer risk: the interplay of polygenic risk, high-impact monogenic variants, and family history
Emadeldin Hassanin, Patrick May, Rana Aldisi, Isabel Spier, Andreas J. Forstner, Markus M. Nöthen, Stefan Aretz, Peter Krawitz, Dheeraj Reddy Bobbili, Carlo Maj
medRxiv 2021.06.04.21258277; doi: https://doi.org/10.1101/2021.06.04.21258277

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (557)
  • Anesthesia (135)
  • Cardiovascular Medicine (1769)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (316)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10812)
  • Forensic Medicine (8)
  • Gastroenterology (594)
  • Genetic and Genomic Medicine (2960)
  • Geriatric Medicine (288)
  • Health Economics (534)
  • Health Informatics (1933)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (293)
  • HIV/AIDS (633)
  • Infectious Diseases (except HIV/AIDS) (12525)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (87)
  • Nephrology (324)
  • Neurology (2808)
  • Nursing (152)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1473)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (868)
  • Pharmacology and Therapeutics (367)
  • Primary Care Research (338)
  • Psychiatry and Clinical Psychology (2646)
  • Public and Global Health (5383)
  • Radiology and Imaging (1016)
  • Rehabilitation Medicine and Physical Therapy (597)
  • Respiratory Medicine (727)
  • Rheumatology (330)
  • Sexual and Reproductive Health (290)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (48)
  • Transplantation (150)
  • Urology (126)